GPIIb-IIIa antagonists: upstream vs deferred use in acute coronary syndromes

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1576, 2007-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

GPIIb-IIIa antagonists cost effective in acute coronary syndromes

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Update on GPIIb/IIIa antagonists

By Hanson Julien de Leval Xavier Kolh Philippe Supuran Claudiu Pirotte Bernard Dogné Jean-Michel

Expert Opinion on Therapeutic Patents, Vol. 13, Iss. 8, 2003-08 ,pp. : 1173-1188

Informa Healthcare

Access to resources Recommend Favorite

Guidance on the use of glycoprotein (GP) IIb/IIIa antagonists in the treatment of acute coronary syndromes

Inpharma, Vol. 1, Iss. 1357, 2002-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Guidance on the use of glycoprotein (GP) IIb/IIIa antagonists in the treatment of acute coronary syndromes

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 385, 2002-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

GP IIb/IIIa receptor antagonists beneficial in acute coronary syndromes

Inpharma, Vol. 1, Iss. 1221, 2000-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite